EYPT (EyePoint Pharmaceuticals, Inc.) Stock Financials & Earnings

EYPTEyePoint Pharmaceuticals, Inc.

Mkt Cap$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$31M

Net Income (TTM)-$232M

EPS (TTM)-$3.16

Free Cash Flow (TTM)-$243M

Gross Margin93.4%

Op. Margin-776.0%

Net Margin-739.4%

FCF Margin-775.8%

P/S Ratio (TTM)42.5x

P/E Ratio (TTM)—

YoY Rev Growth-27.5%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$8M	$7M	-$22M
Q2 23	$9M	$7M	-$23M
Q3 23	$15M	$14M	-$14M
Q4 23	$14M	$13M	-$16M
Q1 24	$12M	$11M	-$33M
Q2 24	$9M	$8M	-$35M
Q3 24	$11M	$10M	-$33M
Q4 24	$12M	$11M	-$45M
Q1 25	$24M	$24M	-$49M
Q2 25	$5M	$5M	-$62M
Q3 25	$966K	$245K	-$62M
Q4 25	$620K	$245K	-$70M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$14M	$9M	$6M
Q2 23	$16M	$9M	$5M
Q3 23	$17M	$11M	$479K
Q4 23	$18M	$11M	$185K
Q1 24	$30M	$14M	$6K
Q2 24	$30M	$13M	$50K
Q3 24	$30M	$13M	$24K
Q4 24	$43M	$13M	$51K
Q1 25	$59M	$14M	$35K
Q2 25	$55M	$12M	$35K
Q3 25	$48M	$14M	$26K
Q4 25	$59M	$11M	—

Revenue Segments

Quarter	License And Collaboration Agreement	Product	Royalty	Y U T I Q Product
Q1 23	$34K	$7M	$255K	—
Q2 23	$4M	$5M	$235K	—
Q3 23	$14M	$816K	$249K	—
Q1 25	$11M	$715K	$13M	$600K
Q2 25	$5M	—	—	—
Q3 25	$150K	$582K	$234K	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$106M	$17M	$122M
Q2 23	$140M	$3M	$143M
Q3 23	$133M	$3M	$136M
Q4 23	$281M	$50M	$331M
Q1 24	$271M	$28M	$299M
Q2 24	$91M	$189M	$280M
Q3 24	$80M	$174M	$254M
Q4 24	$100M	$271M	$371M
Q1 25	$85M	$233M	$318M
Q2 25	$71M	$185M	$256M
Q3 25	$75M	$129M	$204M
Q4 25	$102M	$204M	$306M

Shares Outstanding

Revenue Per Employee

Revenue / Employee